Chugai Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Chairman: Tatsuro Kosaka, hereinafter Chugai Pharmaceutical) and FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) We have signed a license agreement for the use of the support AI system.

　Based on this license agreement, FRONTEO's original natural language analysis AI "Concept Encoder (concept encoder)"^®, Concept encoder) ”, a paper search AI system“ Amanogawa (trademark pending) ”and a new system“ Cascade Eye ”that can visualize the disease mechanism in a pathway shape, utilized in Chugai's drug discovery process Will be done.

　Hiroyoshi Toyoshiba, FRONTEO's Life Science AI CTO, said, "FRONTEO's drug discovery support AI system can instantly display articles and related data that researchers should refer to simply by entering information they want to know or hypotheses they want to verify. Among them, the newly developed "Cascade Eye" is an epoch-making system that can objectively analyze information on various molecules and genes related to diseases and visualize the information in a pathway map. "By combining the technologies of Chugai Pharmaceutical and FRONTEO, we have personalized medicine and unmet medical needs."^{* XNUMX}I think it will lead to the creation of innovations related to high-grade diseases. "

　Satoko Shiji, Executive Officer and General Manager of Digital and IT Administration Department of Chugai Pharmaceutical Co., Ltd., said, "Chugai Pharmaceutical is promoting its own digital transformation in line with our management strategy under" CHUGAI DIGITAL VISION 2030 ". Among them, the utilization of AI in drug discovery research, which is the source of our corporate value, is one of the most important themes. FRONTEO's AI technology is used to deepen understanding of diseases and identify causes and biomarkers of diseases that have not been found so far. By making the best use of, we will shorten the time period, improve the probability of success, and improve the efficiency of the entire process toward the creation of innovative new drugs. "

　We anticipate that this issue alone will have a minor impact on FRONTEO's business results for the fiscal year ending March 2021, but we will promptly announce any reasons that should be disclosed in the future.In addition, the impact of this matter on Chugai's consolidated financial results for the fiscal year ending December 3 will be minor.

* 1 Strong demand for new therapeutic agents and treatment methods for diseases for which no effective treatment method has been found

concept encoderabout　URL: https://lifescience.fronteo.com/concept-encoder/　

"Concept Encoder (concept encoder)^®, Concept Encoder) ”is a natural language analysis AI (artificial intelligence) developed by FRONTEO specializing in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

CHUGAI DIGITAL VISION 2030about　URL: https://www.chugai-pharm.co.jp/profile/digital/index.html

With "CHUGAI DIGITAL VISION 2030" looking ahead to 2030, Chugai aims to be a top innovator that innovates Chugai's business with digital technology and provides healthcare solutions that change society. We will provide healthcare solutions that transform Chugai's business and change society through the three basic strategies of "strengthening the digital infrastructure," "improving the efficiency of all value chains," and "creating innovative new drugs that utilize digital technology." ..

Chugai PharmaceuticalAbout a corporation　URL:https://www.chugai-pharm.co.jp/　

Chugai is a R & D-type R & D-type pharmaceutical company listed on the Tokyo Stock Exchange, which specializes in medical drugs and is headquartered in Tokyo.As an important member of the Roche Group, we are actively engaged in research and development activities for medical drugs in Japan and overseas, and are working to create innovative drugs that meet unmet medical needs.

FRONTEOabout　URL: https://www.fronteo.com/　

FRONTEO Inc. has developed its own natural language analysis AI (artificial intelligence) engine "KIBIT".^®(Kibit) "and" concept encoder^®(Concept encoder) ”is a company that supports information analysis.Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves evidence, investigates and analyzes electronic data necessary for international proceedings, and digital forensic investigations, and technologies such as an in-house developed data analysis platform To date, we have supported about 8 international proceedings.In addition, we are applying the unique AI-related technology cultivated in the legal business to areas such as life science and business intelligence, and have achieved results in drug discovery research support, diagnostic support, and work style reform. Listed on TSE Mothers on June 1, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).